tilray germany
Tilray Deutschland GmbH, a subsidiary of Tilray Brands, manufactures and distributes EU-GMP certified prescription medical cannabis flowers and full-spectrum extracts to physicians, pharmacies, and government health programs across 20 countries, with production facilities in Germany, Portugal, and Canada.
- Company typePrivate
- Founded2017
- HeadquartersDensborn, Germany
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What tilray germany does
Tilray Deutschland GmbH is a wholly-owned German subsidiary of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), established in October 2017 and headquartered in Densborn, Germany. The company manufactures and distributes prescription-grade medical cannabis products — primarily dried cannabis flowers (Cannabisblüten) in multiple cultivars and full-spectrum cannabis extracts (Vollspektrum-Cannabisextrakte) produced via ethanol extraction and standardized with carrier oil for precise THC/CBD concentrations. Manufacturing is anchored in EU-GMP certified facilities in Germany (Neumünster), Portugal, and Canada, with cultivation based on clonal propagation from mother plants to ensure batch-to-batch consistency.
The business operates on a regulated pharmaceutical prescription model: physicians prescribe, pharmacies dispense and compound (Rezepturherstellung), and statutory health insurance (GKV) reimbursement is possible under conditions set by G-BA decisions. Tilray Germany holds import, wholesale, GDP, and narcotics trading authorizations and is listed with the five largest German pharmaceutical wholesalers. It also acts as a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) exporting to 20 countries across five continents, including Luxembourg (government tender), the UK (via CC Pharma and Smartway Pharmaceuticals), Italy (via Tilray Medical Italia and Molteni Farmaceutici), the Czech Republic (Cansativa Group), and Malta. Customers span physicians, pharmacies, hospitals, government health programs, and end patients, with the company supporting 20+ clinical trials and observational studies globally. Go-to-market relies on a Competence Center, field sales representatives, healthcare professional education, conference participation, and the WE CARE digital information platform.
tilray germany firmographics
Firmographics- Name
- tilray germany
- Legal name
- Tilray Deutschland GmbH
- Website
- https://tilraymedical.de
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Short description
- Tilray Deutschland GmbH, a subsidiary of Tilray Brands, manufactures and distributes EU-GMP certified prescription medical cannabis flowers and full-spectrum extracts to physicians, pharmacies, and government health programs across 20 countries, with production facilities in Germany, Portugal, and Canada.
- Ownership category
- akta.pro rank
tilray germany industry classification
Industry- Product category
- Medical Cannabis (pharmaceutical-grade)
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
- akta.pro secondary industries
- Medical Cannabis Dispensaries (CRANAFAB), Medical Cannabis Delivery & Online Ordering (CRANAGAG)
Keywords
Where tilray germany is headquartered
LocationHeadquarters
- HQ city
- Densborn
- HQ country
- Germany
- HQ region
- Europe
Offices9 records
Markets served
tilray germany business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Others
Revenue model
- Prescription Medical Cannabis Products: Tilray Germany manufactures and distributes prescription pharmaceutical-grade cannabis products (dried flowers and full-spectrum extracts) to patients via pharmacies in Germany and for export to 20 countries. Products require a physician's prescription and are dispensed by pharmacies. The company also acts as pharmaceutical entrepreneur (pharmazeutischer Unternehmer) with import, wholesale, and narcotics trading permits.
Go-to-market motion2 records
Distribution channels7 records
Marketing channels7 records
tilray germany product offering
Product offeringCore offering
Tilray Deutschland GmbH manufactures and supplies prescription medical cannabis products—dried cannabis flowers (Cannabisblüten) and full-spectrum cannabis extracts (Vollspektrum-Cannabisextrakte)—from EU-GMP certified facilities. Products are prescribed by physicians and dispensed through pharmacies, with the company also serving as a pharmaceutical entrepreneur holding import, wholesale, and narcotics trading permits. The portfolio supports individualized therapy through THC-dominant, CBD-dominant, and balanced THC/CBD formulations, complemented by a Competence Center providing prescribing, dosing, and reimbursement support to healthcare professionals.
Product overview
Tilray Germany operates as a medical cannabis manufacturer and supplier offering two core product lines: Cannabisblüten (dried cannabis flowers) in various cultivars (Indica, Sativa, Hybrid, CBD-rich) and Vollspektrum-Cannabisextrakte (full-spectrum cannabis extracts) via ethanol extraction. Products serve as prescription medicines for compounding in pharmacies. The portfolio includes THC-dominant, CBD-dominant, and balanced THC/CBD formulations. Supporting services include the Tilray® Cannabis-Ausweis patient ID card and Quick-ID rapid testing products. Products are manufactured in EU-GMP certified facilities in Germany, Portugal, and Canada, with distribution to 20+ countries.
Differentiator
Problem solved
Functional benefit
Products and services
- Cannabisblüten (Cannabis Flowers)
Quantifiable outcome
- 400,000+ patients treated globally with Tilray medical cannabis products
- +5 more outcomes
Companies that use tilray germany
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
tilray germany technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
tilray germany partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- Smartway PharmaceuticalscoreCC Pharma (Tilray's European pharmaceutical trading subsidiary) entered into a strategic agreement with Smartway Pharmaceuticals, a leading UK pharmaceutical distribution group, to improve pharmaceutical product availability across the UK. The agreement leverages Smartway's established national distribution infrastructure and CC Pharma's European sourcing strength and GMP capabilities to accelerate access to medicines, improve supply security, and expand reach through established healthcare channels. This also anchors Tilray within the UK health system for its own medical cannabis products.
- Molteni FarmaceuticicoreTilray Medical Italia (formerly FL Group) partners with Molteni Farmaceutici, one of Italy's leading pharmaceutical companies with extensive experience supplying hospitals, physicians, and pharmacies throughout Italy. The partnership supports medical education, responsible prescribing, and improved patient access while maintaining the highest quality, safety, and compliance standards.
- GEINO (Grupo Español de Investigación en Neuro-Oncología)coreTilray Medical supports an independent clinical study conducted by the Spanish Neuro-Oncology Research Group (GEINO) and the Complutense University of Madrid investigating the efficacy of medical cannabis in treating glioblastomas. Tilray provides pharmaceutical-quality medical cannabis (THC/CBD 1:1) for the Phase I dose-escalation study involving 30 patients across eight specialized neuro-oncology clinics in Spain.
- ONCOWELLNESS (Italy)minorTilray Medical partnered with the ONCOWELLNESS research community for oncology and patient care in Italy by supporting Italy's leading conference for cancer and patient care, accredited by the Italian Ministry of Health. The conference is led by Dr. Vittorio A. Guardamagna and brings together leading Italian physicians from orthopedics, geriatrics, anesthesiology, oncology, and palliative care.
- Cansativa GroupcoreTilray Medical expanded its European presence in the Czech Republic through a new export and distribution partnership with Cansativa Group. The partnership distributes EU-GMP certified medical cannabis products through pharmacies and hospitals to support patient access to medical cannabis in the Czech Republic.
- Hormosan PharmacoreTilray and Hormosan signed a cooperation agreement for the distribution of medical cannabis extracts in Germany. Hormosan supports the distribution and marketing of Tilray's medical cannabis extract products to physicians and pharmacies in the German market.
- DGS (Deutsche Gesellschaft für Schmerzmedizin) / PraxisRegister SchmerzcoreTilray announced support for the non-interventional TIBS (TILRAY Beobachtungsstudie für Schmerz) study in cooperation with the German Pain Society (DGS). The study collected real-world data from 1,000 pain patients treated with cannabinoids over one year, using the existing structures of the DGS PraxisRegister Schmerz.
- University of Sydney (Australia)minorResearch partnership for clinical studies on chemotherapy-induced nausea and vomiting (CINV) and cannabinoids and driving fitness.
- Sick Kids Hospital, Toronto, CanadaminorResearch partnership for clinical studies on pediatric epilepsy / Dravet Syndrome.
- University of British Columbia, CanadaminorResearch partnership for clinical studies on post-traumatic stress disorder (PTSD) and HIV/AIDS-related inflammation.
- McGill University, CanadaminorResearch partnership for clinical studies on chronic obstructive pulmonary disease (COPD) and HIV/AIDS-related inflammation.
- Complutense Universidad, SpainminorResearch partnership for glioblastoma study.
- New York University, USAminorResearch partnership for clinical studies on alcohol use disorder / PTSD.
- Columbia University, New York, USAminorResearch partnership for clinical studies on taxane-induced neuropathies and neuropathic pain.
- University of California San Diego (UCSD), USAminorResearch partnership for clinical studies on essential tremor.
- Murdoch Children's Research Center, AustraliaminorResearch partnership for clinical studies on significant behavioral problems in children with intellectual disabilities.
Scale indicators8 records
Recent moves13 records
Expansion highlights5 records
tilray germany competitors and assessment
Company assessmentDirect peers
- Canopy Growth Corporation: Global medical cannabis producer with EU-GMP operations in Germany and broader Europe. Directly competes with Tilray in the same pharmacy-channel, prescription-based German medical cannabis market.
- Aurora Cannabis: Canadian-headquartered medical cannabis producer with EU-GMP certified German production (Aurora Nordic) and competing flower and extract products supplied through German pharmacies.
- Demecan: German medical cannabis producer with domestic cultivation and EU-GMP certification, selling flowers and extracts directly into the German pharmacy channel — a direct local competitor to Tilray Germany.
- Canify Clinics (formerly Cannamedical): German medical cannabis company supplying EU-GMP cannabis flowers and extracts to pharmacies across Germany; competes directly with Tilray on product range and physician relationships.
- Cansativa Group: German-based cannabis distributor and importer handling both Tilray-branded products and competing EU-GMP lines into German pharmacies — overlapping with Tilray across distribution and select proprietary products.
- Organigram Holdings: Canadian medical and recreational cannabis producer with EU-GMP exports into Germany and other European markets, offering similar flower and extract categories via pharmacy distribution.
Broad incumbents
- Stada Arzneimittel: Major German generic and specialty pharma company that has entered the medical cannabis market with EU-GMP products distributed through German pharmacies, offering broader pharma leverage alongside Tilray's specialist model.
- Dr. Reddy's Laboratories: Global pharmaceutical company that has launched medical cannabis products in select European markets, leveraging established pharma manufacturing and distribution infrastructure to compete with Tilray in regulated European channels.
- Schwabe Group (Dr. Willmar Schwabe): German plant-based pharmaceutical manufacturer that has expanded into cannabis-based prescription medicines, competing in overlapping indications where Tilray's full-spectrum extracts are positioned.
Emerging players
- Sanity Group (Sanatio Pharma / Vayamed): German medical cannabis company with cultivation in Germany and products competing in the pharmacy channel; smaller scale than Tilray but represents an emerging EU-domestic alternative with overlapping products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
tilray germany social profiles
Digital presencetilray germany compliance and trust
Trust signalCompliance2 records
tilray germany financial estimates
Financial estimateRevenue estimate
Valuation estimate
tilray germany leadership team
Management profileNumber of profiles
Profiles6 records
tilray germany subsidiaries and ownership
Company hierarchySubsidiaries2 records
tilray germany funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
tilray germany M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about tilray germany
What does tilray germany do?
Tilray Deutschland GmbH manufactures and supplies prescription medical cannabis products—dried cannabis flowers (Cannabisblüten) and full-spectrum cannabis extracts (Vollspektrum-Cannabisextrakte)—from EU-GMP certified facilities. Products are prescribed by physicians and dispensed through pharmacies, with the company also serving as a pharmaceutical entrepreneur holding import, wholesale, and narcotics trading permits. The portfolio supports individualized therapy through THC-dominant, CBD-dominant, and balanced THC/CBD formulations, complemented by a Competence Center providing prescribing, dosing, and reimbursement support to healthcare professionals.
Is tilray germany a public or private company?
tilray germany is a private company. It is classified as corporate owned and is currently operating.
When was tilray germany founded?
tilray germany was founded in 2017.
Where is tilray germany based?
tilray germany is headquartered in Densborn, Germany, in the Europe region.
How does tilray germany make money?
One revenue line is on record: prescription Medical Cannabis Products.
Who are tilray germany's main competitors?
Direct peers on record are Canopy Growth Corporation, Aurora Cannabis, Demecan, Canify Clinics (formerly Cannamedical), Cansativa Group and Organigram Holdings. Broad incumbents are Stada Arzneimittel, Dr. Reddy's Laboratories and Schwabe Group (Dr. Willmar Schwabe). Sanity Group (Sanatio Pharma / Vayamed) is listed as an emerging player.
Does tilray germany have an API?
No public API is recorded for tilray germany.
What industry is tilray germany in?
tilray germany's product category is Medical Cannabis (pharmaceutical-grade). Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAFAB, Medical Cannabis Dispensaries. Its NAICS code is 325411 and its SIC code is 2834.